Microcap Ledger COMPASS Pathways plc $CMPS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Chesire, United Kingdom
- Fiscal year end
- December 31
- Shares outstanding
- 138,476,822 [10-Q 2026-08-05]
What the company doesAI summary of filing
COMPASS Pathways plc is a clinical-stage biotechnology company developing COMP360, a proprietary psilocybin formulation for mental health conditions. The company is currently advancing two Phase 3 pivotal trials for treatment-resistant depression (TRD), which achieved primary endpoints in 2025 and 2026, with an expected NDA submission in the fourth quarter of 2026. COMPASS is also initiating a Phase 2b/3 trial in post-traumatic stress disorder (PTSD) following FDA acceptance of its IND application in January 2026. The company is pre-revenue and relies on raising capital to fund its clinical development and commercialization planning activities, with plans to launch in the U.S. market by the end of 2026 if FDA approval is obtained. [10-K 2026-03-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$162.59M | −$88.24M | $433.30M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | — | −$269.77M | −$157.24M | $149.61M | [DEF 14A 2026-04-15] |
| FY ended Dec 2024 | — | −$155.12M | −$119.19M | $165.08M | [DEF 14A 2026-04-15] |
- Quarterly cash burn
- −$44.12M
- Cash runway Estimate
- ~29.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 68,420,818 | [10-Q 2024-10-31] |
| 2025-02-24 | 92,673,132 | [10-K 2025-02-27] |
| 2025-05-06 | 93,561,753 | [10-Q 2025-05-08] |
| 2025-07-28 | 95,941,264 | [10-Q 2025-07-31] |
| 2025-10-30 | 96,017,044 | [10-Q 2025-11-04] |
| 2026-03-17 | 128,923,295 | [10-K 2026-03-24] |
| 2026-05-06 | 134,949,320 | [10-Q 2026-05-13] |
| 2026-07-30 | 138,476,822 | [10-Q 2026-08-05] |
- Shelf registration
- S-3ASR filed 2026-08-05 [S-3ASR 2026-08-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-03 | Nath Kabir | other | 5,962 | $11.25 | [4 2026-08-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-05 | S-3ASR | Registration statement |
| 2026-08-05 | 8-K | Results of operations |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-07-07 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-28 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-04-15 | DEF 14A | Proxy statement |
| 2026-03-24 | 10-K | Annual report |
| 2026-03-24 | 8-K | Results of operations |
| 2026-02-19 | 8-K | Material agreement entered; Regulation FD disclosure |
Alerts for $CMPS
Email me when COMPASS Pathways plc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.